Volume 17, Issue 5
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645



From Miracil D® (lucanthone), a hydroxymethyl derivative (hycanthone), can be obtained through the biological activity of the microorganism . This compound was claimed to be the antischistosomal metabolite of Miracil D and was found very active when administered to mice, hamsters, and monkeys experimentally infected with .

Clinical trials with hycanthone were performed on 52 patients with active schistosomiasis mansoni. The drug was administered, , at the dosage levels of 2 and 3 mg per kg per day with an antacid preparation, twice a day, for 5 consecutive days. In all but two patients treatment could be completed. Nausea, vomiting, anorexia, vertigo, and headache were the commonest side-effects. Therapeutic activity could be evaluated in 44 cases by repeated stool examination (four to six) or by one rectal biopsy performed at least 4 months after treatment, or by both. The percentages of patients considered as cured were 83.3 and 80.0 for the schedules of 2 and 3 mg per kg, respectively.

Laboratory and clinical data on the antischistosomal activity of hycanthone obtained so far emphasize the need for further clinical trials with this compound.


Article metrics loading...

The graphs shown below represent data from March 2017
Loading full text...

Full text loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error